It has been 1.5 years since Mayo Clinic opened the world’s first integrated multidisciplinary genomics service, the Individualized Medicine Clinic, which uses genomics and next-generation sequencing technologies to personalise treatments for patients with advanced cancer and complex diagnoses.
In a special issue of the American Journal of Medical Genetics Part C, “Implementation of Genomic Medicine,” developers of the Individualized Medicine Clinic report the clinic’s structure and share lessons learned in everything from efficacy of genomics in patient care to struggles with insurance reimbursement and ethical dilemmas.
Konstantinos Lazaridis, M.D., a Mayo Clinic hepatologist and director of the Individualized Medicine Clinic, says the clinic is a natural extension of Mayo’s commitment to putting the needs of the patient first and that leaders in the Mayo Clinic Center for Individualized Medicine saw this opportunity as an imperative.
Since opening the clinic, more than 30 percent of patients on a diagnostic odyssey have received answers through whole-exome sequencing.
“We now have the capability to understand cancer and diagnostic odyssey cases at their most fundamental level,” says Dr. Lazaridis.
“And while we had many hurdles to overcome in designing and launching this clinic, we continue to improve our services, and that’s what matters to people who need our help.”
The Individualized Medicine Clinic accepts patients on a case-by-case basis and admits those deemed most likely to benefit from next-generation sequencing technologies.
Six lessons learned include:
Source: Mayo Clinic
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.